Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) ...

What Lies Ahead for Praluent? Projections indicate that the Praluent market will continue its upward trajectory in the coming years: .Market Value Forecast: Expected to reach $XX million by 2029.

Fintel reports that on March 11, 2025, Needham initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Buy ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to ...

Ocular Therapeutix (NASDAQ:OCUL) stock rises as Needham rates the company a new Buy, citing the potential of its lead candidate, Axpaxli. Read more here.

The United States Court of Appeals for the First Circuit recently joined the Sixth Circuit (2023) and Eighth Circuit (2022) ...

Treatment options for hyperhidrosis have evolved to include well-tolerated therapies with high rates of response.

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...

with Regeneron putting up the lion's share (almost $120 million), while Illumina is contributing $20 million to its Series C. The cash injection will go towards the Truveta Genome Project ...

Regeneron’s gene therapy for otoferlin-related ... In the ongoing CHORD trial, children receive a single intracochlear injection of DB-OTO in one ear, with the other ear serving as a control.